Lu and Zhou are not just being modest — they’re also being smart. In 2016, it came to light that the NFL had tried to influence concussion research by steering studies toward league-affiliated scientists and by trying to hurt the funding opportunities for scientists who were critical of the league. To Lu and Zhou and their team, it seemed unwise to draw similar attention to their work if they didn’t also propose a clear avenue for the NFL to remedy the situation.
In their study, which builds on their previous research on TBI, they showed not only a molecular link between TBI and CTE but also a possible treatment mechanism — just not one that can be used to treat humans quite yet. They focused their efforts on a particular brain protein called phosphorylated tau, or P-tau, that transforms into a toxic form as a result of brain injury.
“Tau protein is a brain protein important for neurofunction, and in CTE or Alzheimer’s disease, it undergoes some misshaping and eventually forms a tangle, which is a hallmark for Alzheimer’s disease as well as CTE,” Lu explains.
Eventually, these toxic protein tangles build up, which is linked to a wide variety of symptoms including depression, dementia, and aggression.
Using mice, they showed that, after repeated, mild traumatic brain injury, P-tau changes from its typical trans shape to a cis form, which is much more problematic because of its tendency to clump together. This conformation is associated with diseases like Alzheimer’s and, notably, CTE.
In the past, identifying cis P-tau has been a challenge for researchers, since it doesn’t look very different from the trans form. Lu likens it to switching a ring from the index finger to the middle finger.
“There’s so far no tool to detect these toxic proteins,” he says.
His team’s work has changed that. The most promising part of their study is that they laid out a way to not only identify all that problematic cis P-tau but also stop it from collecting and causing problems in the brain. In mice who had experienced severe or repetitive TBI, they were successfully able to use an antibody — a protein designed to latch onto specific molecules — to identify cis P-tau and prevent it from causing damage to the brain.
Now, the trick is figuring out how to make this happen in humans.
Zhou envisions a simple treatment for cis P-tau buildup that involves one or multiple injections of their forthcoming humanized antibody, administered after a person undergoes TBI. It could even be used as a diagnostic tool to identify whether the level of brain injury necessitates treatment, or whether a person’s body can handle clearing the toxic proteins on its own. This will undoubtedly help clarify whether people are actually ever “fine” after a concussion, which has been a contentious issue because some people seem to tolerate multiple TBIs over their lifetimes with no apparent consequences.
Lu and Zhou may never confront the NFL directly, but the troubled league should pay close attention to their work — not because it threatens controversy but because it illuminates a potential solution to the fatal problem plaguing its players. In the future, the NFL will not need to cover up the dangers of playing football if there are clear methods for dealing with the consequences.
“Before our work there was no connection between traumatic brain injury and CTE molecularly,” says Lu. “Right after traumatic brain injury, you don’t see any tau pathology, so people always say, ‘there’s no direct connection,’ and that’s true. But after these papers, I think we can identify there’s a molecular link.”
Now that they’ve identified a molecular link, the next major hurdles are to identify when a person needs treatment and then actually figure out a way to treat them.
“That will dramatically affect the field,” says Lu. “Maybe after a traumatic brain injury, we can give someone three or four injections and they can go back. That would be huge.”